Loading
A phase 2 trial in triple-negative breast cancer, run by Gangnam Severance Hospital, not yet recruiting.
Immune-checkpoint Blockade After Partial Breast Irradiation by Pembrolizumab in Early TNBC is a phase 2, interventional study registered as NCT07011823 by Gangnam Severance Hospital, with a registry enrolment figure of 20 participants, started 2025-07-16 and due to reach its primary completion in 2027-07-31. Interventions recorded: Partial breast-irradiation. Conditions listed: Triple-Negative Breast Neoplasm. Triple-negative eligibility wording from the registry: "* Patients with triple-negative breast cancer confirmed on tissue biopsy". No results are recorded here; the registry entry is the source.
Shares Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.